Compare RDWR & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDWR | VOR |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2000 | 2021 |
| Metric | RDWR | VOR |
|---|---|---|
| Price | $37.17 | $20.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $30.50 | ★ $39.00 |
| AVG Volume (30 Days) | 282.6K | ★ 767.0K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | $59.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.68 | $6.50 |
| 52 Week High | $35.70 | $26.76 |
| Indicator | RDWR | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 74.74 | 56.21 |
| Support Level | $26.53 | $17.35 |
| Resistance Level | N/A | $24.23 |
| Average True Range (ATR) | 1.96 | 1.15 |
| MACD | 0.74 | 0.24 |
| Stochastic Oscillator | 85.67 | 94.33 |
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.